8,935 Shares in Boston Scientific Corporation $BSX Acquired by St. Louis Trust Co

St. Louis Trust Co purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 8,935 shares of the medical equipment provider’s stock, valued at approximately $852,000.

Several other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the last quarter. Invesco Ltd. raised its holdings in Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after acquiring an additional 111,826 shares in the last quarter. Northern Trust Corp raised its holdings in Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after acquiring an additional 128,188 shares in the last quarter. Amundi raised its holdings in Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after acquiring an additional 1,781,830 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in Boston Scientific by 4.6% in the 3rd quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock valued at $1,020,934,000 after acquiring an additional 463,889 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. dropped their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Evercore dropped their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Morgan Stanley dropped their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, Bank of America dropped their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $92.71.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $57.71 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50. The stock has a market capitalization of $85.77 billion, a P/E ratio of 24.15, a price-to-earnings-growth ratio of 1.06 and a beta of 0.62. The stock has a fifty day moving average of $61.97 and a 200-day moving average of $80.25.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.